Company
Micro-X Limited
ASX:MX1
Micro-X designs and manufactures X-ray and CT imaging hardware built on carbon-nanotube ("cold cathode") emitters, which let the tube be far smaller and lighter than conventional thermionic X-ray tubes. Its commercial product is the Rover / Rover Plus mobile digital radiography unit, a portable X-ray system used where patients cannot easily be moved to a fixed radiology suite: emergency departments, intensive care, operating theatres, remote and field settings. In development is an ultra-lightweight head CT scanner intended to be carried in an ambulance so that stroke can be imaged and triaged before the patient reaches hospital, plus earlier-stage portable full-body CT and lung CT work. The longevity relevance is infrastructural rather than therapeutic: it addresses point-of-care imaging for immobile and frail patients and time-to-diagnosis in stroke, a condition whose incidence rises sharply with age. It is not a geroscience or ageing-biology company, and the Micro-X site does not itself market Rover as an aged-care product, so the aged-care framing should be treated as an inference about the use case rather than a company claim. Micro-X also sells non-medical security screening products (baggage and checkpoint scanners), so medical imaging is only part of the revenue base.
At a glance
- Listing
- ASX:MX1
- Category
- Diagnostics
- Headquarters
- Adelaide, South Australia, Australia
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- Diagnostics
- Market
- Australia
- Recent inflection
- On 24 September 2025 Micro-X announced it had been awarded a $4.4 million grant to fund a world-first trial of a stroke-capable ambulance integrating its ultra-lightweight head CT scanner into frontline emergency services. As of the company's 9 July 2026 investor newsletter, the head CT programme had progressed to human imaging trials, alongside portable full-body CT development under the ARPA-H PARADIGM contract (announced 13 February 2025, up to US$16.4m / A$25m). Source: Micro-X news page, micro-x.com/news/.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:MX1 |
| Secondary listing | None |
| Market cap | Not disclosed |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Adelaide, South Australia, Australia
- Website
- micro-x.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
On 24 September 2025 Micro-X announced it had been awarded a $4.4 million grant to fund a world-first trial of a stroke-capable ambulance integrating its ultra-lightweight head CT scanner into frontline emergency services. As of the company's 9 July 2026 investor newsletter, the head CT programme had progressed to human imaging trials, alongside portable full-body CT development under the ARPA-H PARADIGM contract (announced 13 February 2025, up to US$16.4m / A$25m). Source: Micro-X news page, micro-x.com/news/.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Investors — Micro-X Limited (ASX:MX1) · Micro-X Limited
- Micro-X — carbon nanotube X-ray and CT imaging · Micro-X Limited
- News — Micro-X Limited · Micro-X Limited
Every entity profile on variis is sourced. Not investment advice.